ECA
ARKG icon

Elevated Capital Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Elevated Capital Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.98K Hold
47
– – ﹤0.01% 669
2026
Q1 		$1.24K Hold
47
– – ﹤0.01% 709
2025
Q4 		$1.36K Buy
+47
New +$1.41K ﹤0.01% 673
2021
Q3 		$217K Buy
+2,908
New +$244K 0.08% 173

Other funds holding ARKG

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Elevated Capital Advisors's ARKG Position: Q2 2026 in Review

Elevated Capital Advisors held its ARK Genomic Revolution ETF (ARKG) position steady in Q2 2026 at 47 shares worth $1.98K. The position accounts for ﹤0.01% of the portfolio, ranked #669.

Elevated Capital Advisors first reported a position in ARKG in Q3 2021 and has held it in 4 quarters since. The position peaked at $217K in Q3 2021. 271 funds tracked by Wall St. Rank hold ARKG as of Q2 2026.

  • Elevated Capital Advisors held 47 shares of ARK Genomic Revolution ETF worth $1.98K as of Q2 2026.
  • Elevated Capital Advisors left its ARK Genomic Revolution ETF share count unchanged in Q2 2026.
  • ARK Genomic Revolution ETF made up ﹤0.01% of Elevated Capital Advisors's portfolio in Q2 2026, its #669 holding.
  • Elevated Capital Advisors first reported a position in ARK Genomic Revolution ETF in Q3 2021 and has held it in 4 quarters since.
  • Elevated Capital Advisors's ARK Genomic Revolution ETF position peaked at $217K in Q3 2021.
  • 271 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2026.

Based on Elevated Capital Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.